News & Updates

The combination of the anti-PD-1 monoclonal antibody sintilimab with the bevacizumab biosimilar IBI305 and pemetrexed and cisplatin chemotherapy improved progression-free survival (PFS) in patients with EGFR*-mutated (EGFRm) non-squamous non-small-cell lung cancer (NSCLC), according to interim analysis results of the phase III ORIENT-31 trial from China.

The DESKTOP* III trial has shown that patients whose ovarian cancer recurs have better overall survival (OS) following secondary cytoreductive surgery plus platinum-based chemotherapy compared with a platinum-based chemotherapy regimen alone.

The novel third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) aumolertinib appears to be effective in the treatment of patients with EGFR T790M-positive advanced nonsmall cell lung carcinoma (NSCLC) following progression on first- and second-generation EGFR TKI therapy, according to data from the phase II APOLLO Registrational Trial.

A novel algorithm using post-treatment age, albumin, and liver stiffness measurement (LSM), among other parameters, can accurately stratify patients with compensated advanced chronic liver disease (cACLD) according to their de novo hepatocellular carcinoma (HCC) risk, a new study shows.

A remote, proactive, and telephone-based management of toxicities in outpatients during adjuvant or neoadjuvant chemotherapy for early-stage breast cancer does not lead to fewer visits to the emergency department (ED) or hospital admissions, a study has shown.

Adjuvant palbociclib in combination with endocrine therapy (ET) does not improve invasive disease-free survival (iDFS) or secondary endpoints vs ET alone in patients with hormone receptor–positive, HER2-negative early breast cancer, final results of the phase III PALLAS trial have shown.